Lundbeck forges CNS pact with Zenobia, Vernalis

Denmark's Lundbeck has forged development pacts with Vernalis as well as Zenobia Therapeutics on an brain enzyme inhibition program designed to target CNS (central nervous system) ailments such as Parkinson's. Zenobia's technology will be used to crystallize and visualize the enzyme. "These collaborations are important supplements to Lundbeck's commitment to provide new, innovative medicines in the CNS field, in areas with high unmet needs," Lundbeck's Peter Hongaard Andersen, executive vice-president, research management, said in a statement. "It is this type of drug we expect will be in demand in the future." Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.